# Exploring the Therapeutic Potential of Minor Cannabinoids in Dermatology: From Psoriasis to Acne > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/obscure-cannabis-components-hold-therapeutic-promise-for-treating-skin-problems-like-acne-and-psoriasis-study-finds/ > **Published:** 2026-09-04T23:01:53-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:45:56-04:00 > **Clinical Summary:** THCV, CBDV, CBC, CBM, and CBN in dermatology: potential uses in psoriasis, eczema, and acne, the endocannabinoid mechanism, and the precautions. --- [โ† Back to Cannabis News & Clinical Library](https://cedclinic.com/topic-uncategorized/) Table of Contents - [๐Ÿ” CED Perspective Lens: Exploring the Therapeutic Potential of Minor Cannabinoids in Dermatology: From Psoriasis to Acne](#_CED_Perspective_Lens_Exploring_the_Therapeutic_Potential_of_Minor_Cannabinoids_in_Dermatology_From_Psoriasis_to_Acne) - [Introduction](#Introduction) - [Potential Therapeutic Applications of Minor Cannabinoids](#Potential_Therapeutic_Applications_of_Minor_Cannabinoids)[Chart: Minor Cannabinoids and Their Utility in Dermatology](#Chart_Minor_Cannabinoids_and_Their_Utility_in_Dermatology) - [Mechanism of Action: The Endocannabinoid System](#Mechanism_of_Action_The_Endocannabinoid_System) - [Precautions and Risks](#Precautions_and_Risks) - [References](#References)[Summary Notes](#Summary_Notes) - [The Frontier of Minor Cannabinoids in Dermatological Treatments](#The_Frontier_of_Minor_Cannabinoids_in_Dermatological_Treatments)[๐ŸŒ Explore Related CED Clinical Summary Hubs & Research](#_Explore_Related_CED_Clinical_Summary_Hubs_Research) #### ๐Ÿ” CED Perspective Lens: Exploring the Therapeutic Potential of Minor Cannabinoids in Dermatology: From Psoriasis to Acne Dr. Benjamin Caplan, MD **๐ŸŒฑ Clinical Focus:** Detailed evidence review on exploring the therapeutic potential of minor cannabinoids in dermatology: from psoriasis to acne, physiology, and therapeutic applications. **๐Ÿ’ก Clinical Guidance:** Dosing considerations, bioavailability pathways, and evidence-grounded risk management. **๐Ÿ“– Research & Data:** Preserving authoritative charts, diagrams, clinical tables, and scientific reference data. ## Introduction Emerging research in [dermatology](https://cedclinic.com/topic-topical/) indicates that lesser-known cannabinoids, such as THCV, CBDV, CBC, CBM, and CBN, may offer therapeutic benefits for various skin conditions including psoriasis, eczema, and acne. This guide will explore the scientific evidence surrounding the therapeutic promise of these minor cannabinoids in managing dermatological conditions. ## Potential Therapeutic Applications of Minor Cannabinoids ### Chart: Minor Cannabinoids and Their Utility in Dermatology Cannabinoid Skin Conditions Addressed Potential Benefits Known Risks and Limitations THCV Acne Regulates sebum production, exhibits anti-inflammatory and antibacterial properties Limited Clinical Trials CBDV Atopic Dermatitis, Acne Anti-inflammatory, Antioxidant Limited Clinical Trials CBC Acne, Psoriasis, Atopic Dermatitis Anti-inflammatory, Antioxidant Limited Clinical Trials CBM Under investigation Anti-inflammatory Limited Clinical Trials CBN Under investigation Potential anti-inflammatory Limited Clinical Trials ## Mechanism of Action: The Endocannabinoid System The effects of these minor cannabinoids are believed to be mediated by the bodyโ€™s [endocannabinoid system](https://cedclinic.com/topic-body-pathways/), a crucial regulatory mechanism responsible for maintaining the health and proper functioning of various biological processes, including skin functions like immune response, cell proliferation, differentiation, and suppression of inflammation (Kwiecieล„ & Kowalczuk, 2021). ## Precautions and Risks While these minor cannabinoids exhibit promising therapeutic properties, more research is needed to confirm their effectiveness and safety. Issues related to product quality, regulation, legality, and potential health risks should be carefully considered (Kwiecieล„ & Kowalczuk, 2021). For expert advice on cannabinoid use in dermatological conditions, consult Dr. Caplan at CED Clinic. ## References - Kwiecieล„, E., & Kowalczuk, D. (2021). Minor cannabinoids: Therapeutic promise in the management of dermatological diseases. *Molecules*. - Atalay, S., Jarocka-Karpowicz, I., & Skrzydlewska, E. (2019). Antioxidative and Anti-Inflammatory Properties of Cannabidiol. *Antioxidants*. - Ali, A., & Akhtar, N. (2015). The safety and efficacy of 3% Cannabis seeds extract cream for reduction of human cheek skin sebum and erythema content. *Pakistan Journal of Pharmaceutical Sciences*. - Pellati, F., Borgonetti, V., Brighenti, V., Biagi, M., Benvenuti, S., & Corsi, L. (2018). Cannabis sativa L. and Nonpsychoactive Cannabinoids: Their Chemistry and Role against Oxidative Stress, Inflammation, and Cancer. *BioMed Research International*. - ๐Ÿ“— Note: The diagram you see here is based on principles discussed in greater depth in โ€œThe Doctor-Approved Cannabis Handbook.โ€ Enhance your knowledge by purchasing the book directly [through this link](https://amzn.to/4a35lhE)[https://www.amazon.com/Doctor-Approved-Cannabis-Handbook-Wellness-Marijuana/dp/1637742673/ref=sr_1_1?crid=3DJRYIYQCIXOG&keywords=Benjamin+Caplan&qid=1695733542&sprefix=benjamin+caplan%2Caps%2C78&sr=8-1](https://www.amazon.com/Doctor-Approved-Cannabis-Handbook-Wellness-Marijuana/dp/1637742673/ref=sr_1_1?crid=3DJRYIYQCIXOG&keywords=Benjamin+Caplan&qid=1695733542&sprefix=benjamin+caplan%2Caps%2C78&sr=8-1)๐Ÿ“— [https://amzn.to/4a35lhE](https://amzn.to/4a35lhE)[Unlock the world of medical cannabis with The Doctor-Approved Cannabis Handbook.](https://amzn.to/4a35lhE) ### Summary Notes ### The Frontier of Minor Cannabinoids in Dermatological Treatments The therapeutic potential of minor cannabinoids in [dermatology](https://cedclinic.com/topic-topical/) represents a burgeoning area of interest, promising innovative treatments for conditions ranging from psoriasis to acne. Cannabinoids such as cannabigerol (CBG), cannabidivarin (CBDV), and cannabichromene (CBC) are being explored for their anti-inflammatory, antimicrobial, and sebostatic properties, offering new hope for patients with challenging skin conditions. Clinical research and patient testimonies underscore the importance of understanding the unique mechanisms through which these minor cannabinoids exert their effects on the skin, highlighting their potential to complement or even surpass traditional dermatological therapies in terms of efficacy and safety. As the scientific community looks more closely at the dermatological applications of cannabinoids, the development of specialized formulations and delivery systems is key to maximizing their therapeutic benefits. Regulatory, economic, and educational efforts will play crucial roles in integrating cannabinoid-based treatments into mainstream [dermatology](https://cedclinic.com/topic-topical/), ensuring patients have access to safe, effective, and personalized options for skin care and therapy. [โ† Back to Cannabis News & Clinical Library](https://cedclinic.com/topic-uncategorized/) #### ๐ŸŒ Explore Related CED Clinical Summary Hubs & Research [๐Ÿ˜ด Sleep & Insomnia Hub โ†’](https://cedclinic.com/topic-cannabis-sleep-insomnia/) [๐Ÿงฌ Bioavailability Hub โ†’](https://cedclinic.com/topic-bioavailability-pathway-decisions/) [๐Ÿ’Š Clinical Dosing Hub โ†’](https://cedclinic.com/topic-dosage/) [โšก Pain Control Hub โ†’](https://cedclinic.com/topic-pain-control/) --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR ยง 164.514(b)) and criteria for secondary research exemption under 45 CFR ยง 46.104(d)(4).